Pete Pharma and FABRX announce strategic partnership

Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

Indegene opens new center in Pune

Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market

Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product

Eli Lilly appoints Dr. Vivek Jha as Senior Director – Commercial Strategy, AI & Transformation

He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation

FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19

Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Merck and mantro launch EdiMembre to transform alternative protein industry

Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry